Last reviewed · How we verify

NCT07199868: PRP

The Role of Ovarian PRP Therapy in Poseidon Poor Responders Women Undergoing ICSI Cycle

Completed NA Last updated 30 September 2025
What this trial tests

NA trial testing During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle. in Poor Ovarian Reserve in 102 participants. Completed in 28 February 2025.

Timeline
1 January 2024
Primary endpoint
28 February 2025
28 February 2025

Quick facts

Lead sponsorKarbala University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment102
Start date1 January 2024
Primary completion28 February 2025
Estimated completion28 February 2025
Sites2 locations across Iraq

Drugs / interventions tested

Conditions studied

Sponsor

Karbala University

Who can join

Adults 21 to 49, female only, with Poor Ovarian Reserve or Platelet Derived Growth Factor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective : This study aims to evaluate the impact of ovarian PRP therapy compared to control in Poseidon females undergoing ICSI cycles. Material and Methods: A randomized controlled trial was conducted from Jan 2024 to Feb 2025, involving 102 Poseidon women, Participants were divided into a PRP group (n=50), who received ovarian PRP injections and a control group (n=52), who received no PRP. All participants underwent ICSI cycles, embryological and pregnancy outcomes were compared between both groups within each Poseidon group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Poor Ovarian Reserve

Currently open trials in the same condition.

Other Karbala University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07199868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing